Overview:
The
Medical Crossfire®, one of PER’s signature educational formats, is a
video-based program in which a panel of distinguished experts engage in spirted
discussions and debates on a particular clinical topic. In this activity, 3 key thought leaders explore the
latest data regarding the role of menin inhbitors in the treatment of acute
myeloid leukemia (AML). This lively discussion will help place new developments
into clinical context to help you optimize care for your patients with AML.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Determine the mechanistic rationale supporting the role of menin inhibitors in AML treatment
- Discuss the potential implications of recent trial evidence and emerging monotherapy/combination therapy trials evaluating menin inhibitors in patients with AML
- Develop individualized care plans for patients with NPM1m and/or KMT2A-r AML based on clinical trial evidence
- Devise strategies to proactively monitor and mitigate treatment-related toxicities and/or treatment resistance in patients with AML receiving menin inhibitors
